Vita 34 AG Logo

Vita 34 AG

A cell bank storing umbilical cord stem cells as biological insurance for families' future health.

V3V | F

Overview

Corporate Details

ISIN(s):
DE000A0BL849
LEI:
529900OEWA4GSZEZ4P40
Country:
Germany
Address:
Perlickstr. 5, 04103 Leipzig
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Vita 34 AG is a leading European biotechnology company and full-service cell bank specializing in cryopreservation. The company's core services include the collection, processing, and long-term storage of stem cells derived from umbilical cord blood and tissue. These potent hematopoietic and mesenchymal stem cells are preserved for potential future use in regenerative medicine and the treatment of numerous diseases. Established in 1997 as Europe's first private cord blood bank, Vita 34 has consistently been a pioneer in the field. Following a business combination with Polski Bank Komórek Macierzystych S.A., the company has expanded its European leadership and now operates as part of the FamiCord Group, providing families with a form of biological insurance for future health.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-21 07:30
Earnings Release
FamiCord AG accelerates profitable growth in the third quarter of 2025 and furt…
English 19.0 KB
2025-11-21 00:00
Regulatory News Service
Q3 statement / Q3 financial report 2025
English 1.3 MB
2025-09-16 18:53
M&A Activity
FamiCord AG: Polski Bank Komorek Macierzystych sp. z o. o. is to acquire 100 % …
English 6.0 KB
2025-08-27 07:00
Earnings Release
FamiCord AG significantly increases revenue and earnings in the first half of 2…
English 19.8 KB
2025-08-27 00:00
Interim Report
Half-yearly financial report 2025
English 358.1 KB
2025-08-20 13:23
Report Publication Announcement
English 3.9 KB
2025-06-10 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 348.2 KB
2025-05-29 16:19
M&A Activity
FamiCord AG acquires majority stake in Narodni Centrum Pupecnikove Krve and Rod…
English 6.6 KB
2025-05-28 07:00
Earnings Release
FamiCord AG starts 2025 financial year with accelerated growth and increases pr…
English 16.6 KB
2025-05-28 00:00
Quarterly Report
Q1 statement / Q1 financial report 2025
English 675.0 KB
2025-05-19 00:00
Annual Report
Konzernabschluss zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 1.6 MB
2025-05-15 15:05
Pre-Annual General Meeting Information
FamiCord AG: Bekanntmachung der Einberufung zur Hauptversammlung am 25.06.2025 …
German 88.4 KB
2025-04-30 14:09
Earnings Release
FamiCord AG continues growth course in 2024 after strong year-end business and …
English 18.6 KB
2025-04-30 00:00
Annual Report
Annual financial report 2024
English 6.9 MB
2025-04-23 16:18
Report Publication Announcement
English 4.4 KB

Automate Your Workflow. Get a real-time feed of all Vita 34 AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Vita 34 AG

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Vita 34 AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-12-11 AOC Health GmbH Close relation Other None 6,572,680.40 EUR
2023-12-11 Baran, Jakub Julian Other Buy None 99,998.80 EUR
2022-09-28 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy None 21,557.28 EUR
2022-06-02 Dr. Granderath, Rat und Vermögen GmbH Close relation Buy None 33,000.00 EUR
2022-06-02 Schweppe, Thomas Supervisory board Other None N/A
2021-11-18 Lorenzen, Hans-Jochen Supervisory board Sell None 180,625.00 EUR
2021-11-10 Project Mill Gesellschaft für interdisziplinären Know-how-Transfer GmbH Close relation Other None 36,146.25 EUR
2021-11-09 Zeitfracht GmbH & Co. KGaA Close relation Sell None 35,525.00 EUR
2021-11-09 von Blücher, Dietmar Board Buy None 28,820.00 EUR
2021-11-09 von Blücher, Dietmar Board Buy None 14,400.00 EUR

Peer Companies

Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden
ACTI
ACTUATE THERAPEUTICS, INC. Logo
Clinical-stage biopharma developing a novel GSK-3 inhibitor for hard-to-treat cancers.
United States of America
ACTU
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden
ACUC
Acurx Pharmaceuticals, Inc. Logo
Developing a new class of antibiotics to treat priority Gram-positive bacterial infections.
United States of America
ACXP
Adagene Inc. Logo
Develops novel antibody-based immunotherapies for cancer using an AI-driven discovery platform.
United States of America
ADAG
Adaptimmune Therapeutics PLC Logo
Develops novel T-cell therapies to treat solid tumors by engineering a patient's own immune cells.
United States of America
ADAP
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea
179530
ADC Therapeutics SA Logo
Develops targeted antibody-drug conjugates for hematological and solid tumors.
United States of America
ADCT
ADIAL PHARMACEUTICALS, INC. Logo
Develops personalized, genetically-targeted drugs for treating Alcohol Use Disorder and addiction.
United States of America
ADIL
Adicet Bio, Inc. Logo
Developing off-the-shelf gamma delta T cell therapies for cancer and autoimmune diseases.
United States of America
ACET

Talk to a Data Expert

Have a question? We'll get back to you promptly.